Mymetics Corporation: The First Human Vaccinations of Mymetics' Preventative HIV Vaccine Candidate are Well Tolerated

        Print
| Source: Mymetics Corporation

EPALINGES, Switzerland, Jan. 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company’s first preventative HIV vaccine has been well tolerated.

This Phase I trial follows the breakthrough results Mymetics has achieved in macaque monkeys last year. During these pre-clinical studies Mymetics' HIV vaccine provided full protection of vaccinated non-human primates against multiple heterologous live virus challenges, while the placebo group became fully infected. These levels of protection have not been seen before in this type of HIV studies.

HIV, the virus that causes AIDS, infected about 2.7 million new people in 2008, while an estimated 2 million people died in that same period.  HIV related illness remains one of the leading causes of death globally and is projected to continue as a significant global cause of premature mortality in the coming decades.

Until now there has been no vaccine against HIV. "Mymetics vaccine approach is unique in the sense it aims to build protection at the mucosal layer, which is the largest port of entry for many pathogens," stated Jacques Francois Martin, CEO of Mymetics Corp.

"The start of this first Phase I is a very important step for Mymetics in its development of a successful preventative HIV vaccine," stated Sylvain Fleury, Chief Scientific Officer of Mymetics Corp. The placebo controlled, double blinded, single site trial will study the safety and tolerance of the Mymetics HIV preventative vaccine in healthy volunteers. During the last four weeks, the first people have been successfully vaccinated and the vaccine was very well tolerated. In total 24 people will be vaccinated and monitored over a 12 month period.

About Mymetics

Swiss based, US biotechnology company (OTCBB:MYMX) focused on the development of the next generation preventative vaccines for infectious diseases, with 5 vaccines in the pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. Mymetics core technology and know-how is based on the use of virosomes in combination with rationally designed antigens to induce protection acting on early transmission and infection events, including the mucosal immune response as a first barrier against the infection. Mymetics believes this approach allows it to develop preventative vaccines for a broad range of diseases.

Mymetics has started a Phase I for its HIV-1 vaccine. The Phase 1b clinical trial for the Malaria vaccine with children in Tanzania has been completed, while the RSV and the HSV vaccine candidates are in pre-clinical phase. The Influenza virus is out-licensed to Solvay Pharmaceuticals (now Abbott). For further information, please visit: www.mymetics.com

The Mymetics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5478

Forward looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

Mymetics Corporation
Ronald Kempers, COO
+41 21 653 4535
www.mymetics.com